Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Cash & Equivalents (2021 - 2025)

Coeptis Therapeutics Holdings has reported Cash & Equivalents over the past 5 years, most recently at $5.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $5.7 million for Q4 2025, up 964.83% from a year ago — trailing twelve months through Dec 2025 was $5.7 million (up 964.83% YoY), and the annual figure for FY2025 was $5.7 million, up 964.83%.
  • Cash & Equivalents for Q4 2025 was $5.7 million at Coeptis Therapeutics Holdings, up from $4.9 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for COEPW hit a ceiling of $7.4 million in Q3 2022 and a floor of $532885.0 in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $2.1 million (2023), compared with a mean of $2.5 million.
  • Biggest five-year swings in Cash & Equivalents: surged 1160.77% in 2022 and later plummeted 80.85% in 2023.
  • Coeptis Therapeutics Holdings' Cash & Equivalents stood at $2.2 million in 2021, then surged by 73.95% to $3.8 million in 2022, then crashed by 61.25% to $1.5 million in 2023, then crashed by 63.73% to $532885.0 in 2024, then skyrocketed by 964.83% to $5.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $5.7 million (Q4 2025), $4.9 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.